左西孟旦与重组人脑利钠肽联合治疗对急性心力衰竭患者血清炎性因子及心脏功能的影响  

Effects of levosimendan combined with recombinant human brain natriuretic peptide on serum inflammatory factors and cardiac function in patients with acute heart failure

作　　者：庄见群 李莲娜 盛清华 ZHUANG Jian-qun;LI Lian-na;SHENG Qing-hua(Cardiology Department,Center Hospital of Rizhao,Rizhao 276800,China)

机构地区：[1]日照市中心医院心内科,276800 [2]日照市中心医院静脉药物配置中心,276800 [3]日照市中心医院药学部,276800

出　　处：《中国实用医药》2024年第13期98-101,共4页China Practical Medicine

摘　　要：目的 探究左西孟旦与重组人脑利钠肽联合治疗对急性心力衰竭(AHF)患者血清炎性因子及心脏功能的影响。方法 回顾性分析60例AHF患者的临床资料,根据治疗方法的不同将其分为对照组(30例)和观察组(30例)。对照组接受左西孟旦治疗,在此基础上,观察组联合重组人脑利钠肽治疗。对比两组临床效果、血清炎性因子[白介素-10(IL-10)、白介素-17(IL-17)、白介素-6(IL-6)、C反应蛋白(CRP)]、心脏功能[心脏指数(CI)、左室舒张末期内径(LVEDD)、左室射血分数(LVEF)、每搏输出量(SV)]、不良反应发生情况。结果 观察组临床治疗总有效率96.67%较对照组的73.33%高(P<0.05)。治疗后,观察组IL-10(2.94±0.48)ng/L高于对照组的(2.13±0.35)ng/L, IL-17(16.21±3.22)ng/L、IL-6(3.63±0.89)ng/L、CRP(10.18±2.07)mg/L低于对照组的(26.43±5.66)ng/L、(5.17±1.01)ng/L、(14.39±2.58)mg/L(P<0.05)。治疗后,观察组LVEDD(55.22±3.21)mm低于对照组的(59.39±3.85)mm,LVEF(44.94±3.42)%、CI(4.92±0.56)L/min、SV(39.22±3.15)ml高于对照组的(41.15±2.63)%、(4.43±0.34)L/min、(36.23±2.45)ml(P<0.05)。两组不良反应发生率相近,无统计学差异(P>0.05)。结论 AHF患者应用左西孟旦联合重组人脑利钠肽治疗能够更快地调节其炎性因子水平,促进心脏功能改善,且安全性高。Objective To explore the effects of levosimendan combined with recombinant human brain natriuretic peptide on serum inflammatory factors and cardiac function in patients with acute heart failure(AHF).Methods The clinical data of 60 patients with AHF were retrospectively analyzed.According to the different treatment methods,they were divided into a control group(30 cases)and an observation group(30 cases).The control group received levosimendan treatment,on the basis of which,the observation group was combined with recombinant human brain natriuretic peptide treatment.Both groups were compared in terms of clinical effect,serum inflammatory factors[interleukin-10(IL-10),interleukin-17(IL-17),interleukin-6(IL-6),C-reactive protein(CRP)],cardiac function[cardiac index(CI),left ventricular end diastolic diameter(LVEDD),left ventricular ejection fraction(LVEF),and stroke volume(SV)]and adverse reactions.Results The total effective rate of the observation group was 96.67%,which was higher than 73.33%of the control group(P<0.05).After treatment,the observation group had higher IL-10 of(2.94±0.48)ng/L than(2.13±0.35)ng/L in the control group;the observation group had IL-17 of(16.21±3.22)ng/L,IL-6 of(3.63±0.89)ng/L and CRP of(10.18±2.07)mg/L,which were lower than(26.43±5.66)ng/L,(5.17±1.01)ng/L and(14.39±2.58)mg/L in the control group(P<0.05).After treatment,the observation group had lower LVEDD of(55.22±3.21)mm than(59.39±3.85)mm in the control group;the observation group had LVEF of(44.94±3.42)%,CI of(4.92±0.56)L/min and SV of(39.22±3.15)ml,which were higher than(41.15±2.63)%,(4.43±0.34)L/min and(36.23±2.45)ml in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion In patients with AHF,levosimendan combined with recombinant human brain natriuretic peptide therapy can regulate their inflammatory factors more quickly and promote the improvement of cardiac function with high safety.

关 键 词：急性心力衰竭 左西孟旦 重组人脑利钠肽 血清炎性因子 心脏功能 

分 类 号：R541.6[医药卫生—心血管疾病]